Search Results - "Darko, Miljkovic"

FIVE TIMES SIT TO STAND TEST IS A PREDICTOR OF RECURRENT FALLS IN HEALTHY COMMUNITY-LIVING SUBJECTS AGED 65 AND OLDER by Buatois, Severine, Miljkovic, Darko, Manckoundia, Patrick, Gueguen, Rene, Miget, Patrick, Vançon, Guy, Perrin, Philippe, Benetos, Athanase

Get full text

Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study by Kuo, Ching-Yuan, Wang, Po-Nan, Hwang, Wen-Li, Tzeng, Cheng-Hwai, Bai, Li-Yaun, Tang, Jih-Luh, Chang, Ming-Chih, Lin, Sheng-Fung, Chen, Tsai-Yun, Chen, Yeu-Chin, Tan, Tran-Der, Hsieh, Chih-Yi, Lin, Chinjune, Lai, Clinton, Miljkovic, Darko, Chang, Cheng-Shyong

“…Background: Nilotinib, a second-generation tyrosine kinase inhibitor (TKI), is approved for the treatment of patients with chronic myeloid leukemia (CML) in…”
Get full text

TARGET: a survey of real‐world management of chronic myeloid leukaemia across 33 countries by Turkina, Anna, Wang, Jianxiang, Mathews, Vikram, Saydam, Guray, Jung, Chul Won, Al Hashmi, Hani Hassan, Yassin, Mohamed, Le Clanche, Solenn, Miljkovic, Darko, Slader, Cassandra, Hughes, Timothy P.

“…Summary Despite the availability of guidelines for the management of chronic myeloid leukaemia (CML), various issues may prevent their successful…”
Get full text

International real-world study of DLL3 expression in patients with small cell lung cancer by Rojo, Federico, Corassa, Marcelo, Mavroudis, Dimitrios, Öz, Aysim Büge, Biesma, Bonne, Brcic, Luka, Pauwels, Patrick, Sailer, Verena, Gosney, John, Miljkovic, Darko, Hader, Carlos, Wu, Meijing, Almarez, Todd, Penault-Llorca, Frédérique

“…•This is the largest epidemiologic study to evaluate DLL3 prevalence in SCLC.•DLL3 was robustly expressed in SCLC across disease stages and lines of…”
Get full text

Efficacy and safety profile of long‐term exposure to lenalidomide in patients with recurrent multiple myeloma by Fouquet, Guillemette, Tardy, Stéphanie, Demarquette, Hélène, Bonnet, Sarah, Gay, Julie, Debarri, Houria, Herbaux, Charles, Guidez, Stéphanie, Michel, Jessica, Perrot, Aurore, Serrier, Caroline, Miljkovic, Darko, Avet Loiseau, Hervé, Facon, Thierry, Hulin, Cyrille, Leleu, Xavier

“…BACKGROUND Lenalidomide in combination with dexamethasone (Len/Dex) is indicated for patients with recurrent/refractory multiple myeloma (RRMM) who were…”
Get full text

Blood pressure and pulse wave velocity values in the institutionalized elderly aged 80 and over: baseline of the PARTAGE study by Benetos, Athanase, Buatois, Severine, Salvi, Paolo, Marino, Francesca, Toulza, Olivier, Dubail, Delphine, Manckoundia, Patrick, Valbusa, Filippo, Rolland, Yves, Hanon, Olivier, Gautier, Sylvie, Miljkovic, Darko, Guillemin, Francis, Zamboni, Mauro, Labat, Carlos, Perret-Guillaume, Christine

“…OBJECTIVEThe aim of the longitudinal study PARTAGE (predictive values of blood pressure and arterial stiffness in institutionalized very aged population) was…”
Get full text

Safety and Efficacy of Nilotinib (NIL) in Patients (Pts) with Chronic Phase (CP) or Accelerated Phase (AP) Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib Mesylate (IM): Results from the Multicenter, Observational NOVEL Study in Taiwan by Kuo, Ching-Yuan, Wang, Po-Nan, Hwang, Wen Li, Tzeng, Cheng-Hwai, Bai, Li-Yuan, Tang, Jih-Luh, Chang, Ming-Chih, Lin, Sheng-Fung, Chen, Tsai-Yun, Chen, Yeu-Chin, Tan, Tran-Der, Hseih, Chih-Yi, Lin, Chinjune, Darko, Miljkovic, Cheng-Shyong, Chang

“…▪ Background: The selective tyrosine kinase inhibitor (TKI) NIL is approved for the treatment of IM resistant CML-CP or CML-AP pts globally, including Taiwan…”
Get full text

Correlation Between Peripheral Blood Pressure and Pulse-Wave Velocity Values in the Institutionalized Elderly Persons 80 Years of Age and Older: The PARTAGE Study by Miljkovic, Darko, Perret-Guillaume, Christine, Alla, François, Salvi, Paolo, Erpelding, Marie-Line, Benetos, Athanase

“…BACKGROUND Carotid-femoral pulse-wave velocity (PWV) provides a comprehensive noninvasive indication of arterial stiffness, and is now established as a strong…”
Get full text

Efficacy and Safety Profile of Long Term Exposure to Lenalidomide in Relapsed Multiple Myeloma by Fouquet, Guillemette, Tardy, Stéphanie, Demarquette, Helene, Bonnet, Sarah, Gay, Julie, Debarri, Houria, Herbaux, Charles, Michel, Jessica, Perrot, Aurore, Serrier, Caroline, Robinson, Suzanne K., Miljkovic, Darko, Morel, Pascale, Boccacio, Catherine, AvetLoiseau, Herve, Facon, Thierry, Hulin, Cyrille, Leleu, Xavier

“…Abstract 2964 Lenalidomide is an oral IMiD®, immunomodulatory compound, approved for use in combination with dexamethasone (Len/Dex) in patients with RRMM who…”
Get full text

Abstract 2011: A Simple Nomogram to Predict the Probability of Successful Reperfusion with Pre-Hospital Thrombolysis by Bongard, Vanina, Puel, Jacques, Savary, Dominique, Charpentier, Sandrine, Belle, Loic, Loubeyre, Christophe, Miljkovic, Darko, Ingelheim, Boehringer, Cottin, Yves, Steg, Philippe G, Elbaz, Meyer

“…Abstract only In ST-elevation myocardial infarction (STEMI), coronary recanalisation is a prerequisite for deriving benefit from thrombolysis, but achieving…”
Get full text

A simple nomogram for early prediction of myocardial reperfusion after pre-hospital thrombolysis by ROSENCHER, Julien, BONGARD, Vanina, PUEL, Jacques, CHARPENTIER, Sandrine, TAZAROURTE, Karim, SOULAT, Louis, SAVARY, Dominique, ELBAZ, Meyer, MILJKOVIC, Darko, COTTIN, Yves, LAMBERT, Yves, STEG, Gabriel

“…To discriminate early ST-segment elevation myocardial infarction (STEMI) presenters at a high probability of successful pre-hospital thrombolysis (PHT) using a…”
Get full text